Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-27T13:31:22.807Z Has data issue: false hasContentIssue false
  • English
  • Français

Correlation between liver cirrhosis and risk of death from oral cancer: Taiwan cohort study

Published online by Cambridge University Press:  10 May 2016

K-P Chang ,
C-C Lee ,
Y-C Su ,
M-L Han ,
T-H Kung  and
H-J Chang
K-P Chang
Affiliation:
Department of Otorhinolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan School of Medicine, National Defense Medical Center, Taipei, Taiwan Department of Otolaryngology, Head and Neck Surgery, Tri-Service General Hospital, Taipei, Taiwan
C-C Lee
Affiliation:
Department of Otorhinolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan School of Medicine, National Defense Medical Center, Taipei, Taiwan Department of Otolaryngology, Head and Neck Surgery, Tri-Service General Hospital, Taipei, Taiwan
Y-C Su
Affiliation:
Division of Hema-Oncology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
M-L Han
Affiliation:
Department of Gastroenterology, Min-Sheng General Hospital, Taoyuan, Taiwan
T-H Kung
Affiliation:
Department of Gastroenterology, Min-Sheng General Hospital, Taoyuan, Taiwan
H-J Chang*
Affiliation:
Department of Radiation Oncology, Min-Sheng General Hospital, Taoyuan, Taiwan
*
Address for correspondence: Dr Heng-Jui Chang, Department of Radiation Oncology, Min-Sheng General Hospital, Taoyuan, Taiwan No. 168, Jingguo Rd, Taoyuan Dist, Taoyuan City 330, Taiwan E-mail: bryancgu@yahoo.com.tw
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

A nationwide population-based cohort was used to examine the severity of liver cirrhosis and risk of mortality from oral cancer.

Methods:

The cohort consisted of 3583 patients with oral cancer treated by surgery between 2008 and 2011 in Taiwan. They were grouped on the basis of normal liver function (n = 3471), cirrhosis without decompensation (n = 72) and cirrhosis with decompensation (n = 40). The primary endpoint was mortality. Hazard ratios of death were also determined.

Results:

The mortality rates in the respective groups were 14.8 per cent, 20.8 per cent and 37.5 per cent at one year (p < 0.001). The adjusted hazard ratios of death at one year for each group compared to the normal group were 2.01 (p = 0.021) for cirrhotic patients without decompensation, 4.84 (p < 0.001) for those with decompensation and 2.65 (p < 0.001) for those receiving chemotherapy.

Conclusion:

Liver cirrhosis can be used to predict one-year mortality in oral cancer patients. Chemotherapy should be used with caution and underlying co-morbidities should be managed in cirrhotic patients to reduce mortality risk.

Keywords

CirrhosisOral CancerHead And Neck CancerMortalityRiskCohort StudiesDatabase
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 130 , Issue 6 , June 2016 , pp. 565 - 570
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Health Promotion Administration Ministry of Health and Welfare, Taiwan. Cancer Registry Annual Report 2011, Taiwan; February 2014. In: http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201404160001 [10 April 2015]Google Scholar
2 Perkins, TM, Perkins, I. Chronic alcoholism: a common risk factor in oral cancer and alcoholic cirrhosis. Compend Contin Educ Dent 2001;22:49–51 Google ScholarPubMed
3 Friedman, LS. The risk of surgery in patients with liver disease. Hepatology 1999;29:1617–23Google Scholar
4 O'Leary, JG, Yachimski, PS, Friedman, LS. Surgery in the patient with liver disease. Clin Liver Dis 2009;13:211–31Google Scholar
5 Friedman, LS. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc 2010;121:192–205 Google Scholar
6 Farnsworth, N, Fagan, SP, Berger, DH, Awad, SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004;188:580–3Google Scholar
7 Suman, A, Barnes, DS, Zein, NN, Levinthal, GN, Connor, JT, Carey, WD. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2004;2:719–23Google Scholar
8 Neeff, H, Mariaskin, D, Spangenberg, HC, Hopt, UT, Makowiec, F. Perioperative mortality after non-hepatic general surgery in patients with liver cirrhosis: an analysis of 138 operations in the 2000s using Child and MELD scores. J Gastrointest Surg 2011;15:1–11 Google Scholar
9 Hanje, AJ, Patel, T. Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol 2007;4:266–76Google Scholar
10 Klemperer, JD, Ko, W, Krieger, KH, Connolly, M, Rosengart, TK, Altorki, NK et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg 1998;65:85–7Google Scholar
11 Filsoufi, F, Salzberg, SP, Rahmanian, PB, Schiano, TD, Elsiesy, H, Squire, A et al. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl 2007;13:990–5Google Scholar
12 Shaheen, AA, Kaplan, GG, Hubbard, JN, Myers, RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. Liver Int 2009;29:1141–51CrossRefGoogle ScholarPubMed
13 Liao, JC, Chen, WJ, Chen, LH, Niu, CC, Fu, TS, Lai, PL et al. Complications associated with instrumented lumbar surgery in patients with liver cirrhosis: a matched cohort analysis. Spine J 2013;13:908–13Google Scholar
14 Wu, CC, Yeh, DC, Lin, MC, Liu, TJ, P'Eng, FK. Improving operative safety for cirrhotic liver resection. Br J Surg 2001;88:210–15Google Scholar
15 Schroeder, RA, Marroquin, CE, Bute, BP, Khuri, S, Henderson, WG, Kuo, PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006;243:373–9CrossRefGoogle ScholarPubMed
16 Clavien, PA, Petrowsky, H, DeOliveira, ML, Graf, R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545–59Google Scholar
17 Demetriades, D, Constantinou, C, Salim, A, Velmahos, G, Rhee, P, Chan, L. Liver cirrhosis in patients undergoing laparotomy for trauma: effect on outcomes. J Am Coll Surg 2004;199:538–42Google Scholar
18 Lekholm, U, Stenman, G. Induction of oral cancer by 7,12-dimethylbenz[a]anthracene in rats with liver cirrhosis. Acta Odontol Scand 1989;47:265–9Google Scholar
19 Randi, G, Altieri, A, Gallus, S, Franceschi, S, Negri, E, Talamini, R et al. History of cirrhosis and risk of digestive tract neoplasms. Ann Oncol 2005;16:1551–5Google Scholar
20 Kao, HK, Chang, KP, Ching, WC, Tsao, CK, Cheng, MH, Wei, FC. The impacts of liver cirrhosis on head and neck cancer patients undergoing microsurgical free tissue transfer: an evaluation of flap outcome and flap-related complications. Oral Oncol 2009;45:1058–62Google Scholar
21 Chang, PH, Yeh, KY, Huang, JS. Competing causes of death in patients with oral cavity cancer in a single cancer center in Taiwan. J Cancer Res Pract 2013;29:14–21 Google Scholar
22 Chang, TS, Chang, CM, Hsu, TW, Lin, YS, Lai, NS, Su, YC et al. The combined effect of individual and neighborhood socioeconomic status on nasopharyngeal cancer survival. PLoS One 2013;8:e73889Google Scholar
23 Su, FH, Chang, SN, Chen, PC, Sung, FC, Huang, SF, Chiou, HY et al. Positive association between hepatitis C infection and oral cavity cancer: a nationwide population-based cohort study in Taiwan. PLoS One 2012;7:e48109Google Scholar
24 Goldacre, MJ, Wotton, CJ, Yeates, D, Seagroatt, V, Collier, J. Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study. Eur J Gastroenterol Hepatol 2008;20:384–92Google Scholar
25 Perz, JF, Armstrong, GL, Farrington, LA, Hutin, YJ, Bell, BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–38CrossRefGoogle ScholarPubMed
26 Sung, JL, Chen, DS. Hepatitis B antigen and antibody in liver disease in Taiwan. In: Lee, SK, ed. Proceedings of the 5th Asian Pacific Congress of Gastroenterology, 23–27 May, 1976, Singapore. Singapore: Asian Pacific Congress of Gastroenterology, 1976;265–9Google Scholar
27 Poschl, G, Seitz, HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155–65Google Scholar
28 Jepsen, P, Vilstrup, H, Andersen, PK, Lash, TL, Sorensen, HT. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology 2008;48:214–20Google Scholar
29 Chang, TT, Gish, RG, Man, RD, Gadano, A, Sollano, J, Chao, YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001–10Google Scholar
30 Lai, CL, Shouval, D, Lok, AS, Chang, TT, Cheinquer, H, Goodman, Z et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–20Google Scholar
31 Köklü, S, Tuna, Y, Gülşen, MT, Demir, M, Aydin, SK, Muhammet, CK et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013;11:88–94 CrossRefGoogle ScholarPubMed
32 Ao, ZH, Xu, ZH, Lu, ZM, Xu, HY, Zhang, XM, Dou, WF et al. Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases. J Ethnopharmacol 2009;121:194–212 Google Scholar
33 Hseu, YC, Chang, WC, Hseu, YT, Lee, CY, Yech, YJ, Chen, PC et al. Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci 2002;71:469–82CrossRefGoogle ScholarPubMed
34 Lin, WC, Kuo, SC, Lin, WL, Fang, HL, Wang, BC. Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2006;12:2369–74Google Scholar
35 Shu, CH, Lung, MY. Effect of pH on the production and molecular weight distribution of exopolysaccharide by Antrodia camphorata in batch cultures. Process Biochem 2004;39:931–7Google Scholar
36 Haddad, Y, Vallerand, D, Brault, A, Haddad, PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2011;2011:nep164Google Scholar
37 Al-Anati, L, Essid, E, Reinehr, R, Petzinger, E. Silibinin protects OTA-mediated TNF-a release from perfused rat livers and isolated rat Kupffer cells. Mol Nutr Food Res 2009;53:460–6CrossRefGoogle Scholar
38 Kostek, H, Szponar, J, Tchórz, M, Majewska, M, Lewandowska-Stanek, H. Silibinin and its hepatoprotective action from the perspective of a toxicologist [in Polish]. Przegl Lek 2012;69:541–3Google Scholar